Good news, bad news for Mannkind's inhaled insulin system

Company releases test results showing that its Technosphere insulin delivery system is as effective for diabetics as injections. But investors are still wary about safety, and Mannkind's stock slumps. Even after biotechnology company MannKind Corp. released new data on its experimental insulin inhaler today, the Valencia-based company has been unable to assuage the safety concerns that decimated its stock in April.

Read the whole article on LA Times - Science

More from LA Times - Science